Answers are grounded in this paper and cite their sources.
Osteoarthritis (OA) lacks effective disease-modifying therapies. This study evaluated the therapeutic potential of alginic acid (AA), which was identified through a FOXO3a-oriented virtual screening strategy, and investigated its downstream regulatory mechanism with a focus on the EREG-MAPK signaling axis. AA was prioritized through structure-based virtual screening against FOXO3a followed by functional secondary screening. In vitro, IL-1β-stimulated human OA chondrocytes were treated with AA and assessed for extracellular matrix metabolism, inflammation, apoptosis, and MAPK pathway activity. FOXO3a knockdown and EREG-overexpression rescue experiments were performed to evaluate the functional roles of FOXO3a and EREG. In vivo, DMM-induced OA rats received intra-articular AA treatment, followed by assessment of pain behavior, cartilage pathology, and matrix preservation. Transcriptomic analysis was used to identify AA-responsive genes and signaling pathways under OA-like inflammatory conditions. AA promoted cartilage matrix synthesis, reduced matrix degradation and inflammatory responses, and attenuated chondrocyte apoptosis in vitro. In DMM-induced OA rats, AA alleviated pain hypersensitivity and reduced cartilage degeneration. Transcriptomic and subsequent validation analyses identified EREG and MAPK signaling as AA-responsive components. AA reduced EREG expression and MAPK phosphorylation. Importantly, FOXO3a knockdown markedly attenuated the effects of AA on EREG expression, p38 MAPK activation, and cartilage matrix homeostasis, supporting a functional requirement for FOXO3a in AA-mediated chondroprotection. Conversely, EREG overexpression partially counteracted the protective effects of AA. AA exerts chondroprotective effects in experimental OA and appears to act, at least in part, through FOXO3a-dependent suppression of EREG-MAPK signaling. These findings strengthen the mechanistic basis for AA as a potential OA therapeutic candidate while supporting further investigation of the FOXO3a-EREG-MAPK regulatory axis.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: